Literature DB >> 10491123

Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain.

J Eck1, M Langer, B Möckel, A Baur, M Rothe, H Zinke, H Lentzen.   

Abstract

Mistletoe lectin I (MLI) is the major active constituent of mistletoe extracts, which are widely used for adjuvant tumour therapy. The 66-kDa heterodimeric disulphide-linked glycoprotein is classified as type II ribosome-inactivating protein (RIP) due to the rRNA-cleaving enzyme activity of the A-subunit, also referred to as toxic entity. MLI and the close relative ricin both belong to the family of the two-chain plant type II RIP proteins. Isolation of the glycosylated proteins from plant material yield inhomogeneous material probably due to post-translational modifications. The aim of this study was to prepare pure and homogeneous protein as a prerequisite for structural and mechanistic studies in order to gain insight into the mode of action of this cytotoxic plant protein on tumour and immune cells. Of particular interest was to explain whether the differences in toxicity of ML and ricin are the result of variations of their enzymatic activities. By investigating the sequence homologies between the active sites of different RIPs we were able to deduce a set of primers which were suitable for specific amplification of the mistletoe lectin gene. Applying this PCR strategy the full-length 1923 nucleotide DNA sequence coding for the prepro-protein was obtained showing the existence of a single intron-free gene. In order to elucidate the molecular basis for the observed differences in cytotoxicity within the family of RIP the enzymatic A-subunit was expressed in a heterologous system. Expression of the A-chain in E. coli BL21/pT7 resulted in production of insoluble inclusion bodies constituting 20-30% of total protein. Refolding led to a pure and homogeneous protein species with an apparent molecular mass of 27 kDa and a pI value of 6.4. The ribosome-inactivating activity of the unglycosylated recombinant A-chain (IC50 20.5 pM) protein was in the same range as that of the glycosylated plant-derived ML A-chain (IC50 3.7 pM), which was very similar to that of ricin A-chain (IC50 4.9 pM). Thus, the higher cytotoxicity of ricin cannot be accountable for differences in the enzymatic activities of the type II RIP A-chains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491123     DOI: 10.1046/j.1432-1327.1999.00638.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  14 in total

1.  Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro.

Authors:  U Elsässer-Beile; M Voss; R Schühle; U Wetterauer
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.

Authors:  Gabriele Gamerith; Arno Amann; Bettina Schenk; Thomas Auer; Hans Lentzen; Dirk O Mügge; Katharina M Cima; Judith Löffler-Ragg; Wolfgang Hilbe; Heinz Zwierzina
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

3.  Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; O Leavy; E McNeela; K H G Mills; D T O'Hagan
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

4.  Huqi San-Evoked Rat Colonic Anion Secretion through Increasing CFTR Expression.

Authors:  Xiaowei Xue; Zhengming Shi; Wen Wang; Xiaotong Yu; Ping Feng; Min Zhang; Xuejiang Wang; Jingdong Xu
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-28       Impact factor: 2.629

Review 5.  Ribosome-inactivating and related proteins.

Authors:  Joachim Schrot; Alexander Weng; Matthias F Melzig
Journal:  Toxins (Basel)       Date:  2015-05-08       Impact factor: 4.546

Review 6.  The immunomodulatory effect of plant lectins: a review with emphasis on ArtinM properties.

Authors:  Maria A Souza; Fernanda C Carvalho; Luciana P Ruas; Rafael Ricci-Azevedo; Maria Cristina Roque-Barreira
Journal:  Glycoconj J       Date:  2013-01-09       Impact factor: 2.916

7.  Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.

Authors:  Uwe Trefzer; Ralf Gutzmer; Tabea Wilhelm; Florian Schenck; Katharina C Kähler; Volkmar Jacobi; Klaus Witthohn; Hans Lentzen; Peter Mohr
Journal:  J Immunother Cancer       Date:  2014-08-19       Impact factor: 13.751

8.  Identification of Viscum album L. miRNAs and prediction of their medicinal values.

Authors:  Wenyan Xie; Jacob Adolf; Matthias F Melzig
Journal:  PLoS One       Date:  2017-11-07       Impact factor: 3.240

9.  Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation.

Authors:  K Hostanska; V Vuong; S Rocha; M S Soengas; C Glanzmann; R Saller; S Bodis; M Pruschy
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

10.  Molecular cloning and in-depth bioinformatics analysis of type II ribosome-inactivating protein isolated from Sambucus ebulus.

Authors:  Masoumeh Rezaei-Moshaei; Ali Bandehagh; Ali Dehestani; Ali Pakdin-Parizi; Majid Golkar
Journal:  Saudi J Biol Sci       Date:  2020-02-17       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.